BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 StudySusan Bal, Jesús G. Berdeja, Hongxiang Hu et al.|Blood|2023Cited by 56
Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label StudySusan Bal, Jesús G. Berdeja, Mehmet H. Kocoglu et al.|Blood|2022Cited by 39
S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDYSusan Bal, Omar Nadeem, Jesús G. Berdeja et al.|HemaSphere|2023Cited by 15
P-037 BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 studyOmar Nadeem, Susan Bal, Jesús G. Berdeja et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0
Facilitating RP2D decisions for CAR T cell therapy clinical studies using a QSP modelAlexander V. Ratushny, Safiyyah Ziyad, Steven L. Chang et al.|Unknown|2024Cited by 0